Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (August 2015)
30 slides from Syngene International's investor presentation, August 2015
Slide 1: Investor Presentation
Investor Presentation August 2015 Strictly confidential & privileged
Slide 2: Safe Harbour
Safe Harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 3: Highlights
Highlights 1 Introduction 2 Industry Overview 3 Investment Thesis 4 Financial Highlights 3
Slide 4: Introduction
Introduction . 7 . + " » * * . waa eas! Putting Science to Work
Slide 5: The Biocon Group
The Biocon Group THE BIOCON GROUP Listed since 2004, Market Cap ~INR 92.3bn(1) Biosimilars Contract Discovery Product Service Formulations and Compounds Contract Development Based Based Alternative Therapeutic Drugs Contract Manufacturing 5 (1) As of 30th June 2015 Strictly confidential
Slide 6: Ownership Structure
Ownership Structure Total number of shares: 200 Mn Promoter : Biocon Group(1) Biocon ESOP 1.0% Public consists of - Syngene ESOP 3.3% Promoter o Silver leaf : 10% 73.5% Public o Other Shareholders : 12.2% 22.2% 6 (1) Includes stake of Biocon Limited, Biocon Research Limited and Kiran Mazumdar
Slide 7: Syngene – 21 Years of Growth and Expansion
Syngene – 21 Years of Growth and Expansion 20,000 sq ft facility Over 900,000 sq ft facility Infrastructure 100+ 2,700+ People - Chemistry - Early biology - End-to-End discovery, development and - Simple biology laboratory manufacturing capabilities Capabilities $5 million $150 million Investment 7
Slide 8: Who We Are Today: A Global High Growth CRO Company
Who We Are Today: A Global High Growth CRO Company One of the leading India-based CROs Strong Growth and Profitability Integrated discovery and development platform Focus on novel molecular entities 8,716 221(1) clients across multiple sectors 7,077 5,542 95%(1) of revenues from outside India 4,182
Slide 9: Recent Business Highlights
Recent Business Highlights All figures in INR Mn unless otherwise specified Entered into 3 long-term contracts with two existing P&L Summary Q1 FY16 Q1 FY15 YoY Change clients for commercial manufacturing of their novel Revenue 2,358 1,833 29% small molecules EBITDA 770 618 25% Extended our long
Slide 10: Industry Overview
Industry Overview . . 7 . + " » * * . waa eas! Putting Science to Work
Slide 11: Global Pharma R&D Trends
Global Pharma R&D Trends Large and growing addressable market Industry Statistics Global R&D expenditure expected to increase from (US$bn) $139bn in 2014 to $152bn in 2018 (CAGR of 2.3%) Global R&D Spending Global CRO Market(1) 75% of R&D spend can be potentially outsourced 45 Increasing per
Slide 12: Investment Thesis
Investment Thesis . . 7 . + " » * * . waa eas! Putting Science to Work
Slide 13: What Makes Syngene A Unique Investment case?
What Makes Syngene A Unique Investment case? INTEGRATED MODEL Integrated and flexible model provides predictability and scalability WORLD CLASS INFRASTRUCTURE & SCIENTISTS World class infrastructure, high standards of quality systems and a highly talented pool of scientists underpins the continuous
Slide 14: Fully Integrated Services Platform
Fully Integrated Services Platform Discovery Development Manufacturing Drug Substance Chemistry Development Clinical Supplies Small Molecules Drug Product Development Biology Integrated Drug Substance – Specialty Molecules Drug Product Integrated drug discovery Clinical Services (India) Commercial S
Slide 15: Integrated platform with multiple entry points
Integrated platform with multiple entry points Entry points create opportunity for customer engagement expansion Discovery Development Commercialisation Pre- clinical Clinical Target Lead Product Identification Generation Animal Ph Ph Ph Drug filing launch Lead Safety I II III with FDA & other globa
Slide 16: Integrated platform enables us to build strategic relationships
Integrated platform enables us to build strategic relationships 16
Slide 17: CRO industry has high barriers to entry
CRO industry has high barriers to entry R&D and Manufacturing Infrastructure Conform with international accreditations Focus on Quality Quality certified processes and instruments Intellectual Property Protection Strong IP and confidentiality procedures Scientist Talent Ability to attract global sci
Slide 18: World-class R&D & Manufacturing Facilities
World-class R&D & Manufacturing Facilities Infrastructure Qualified to Meet International Standards Key accreditations USFDA EMA Over 900,000 sq. ft. of labs and manufacturing facilities audited audited INR 9,569 Mn(1) total tangible fixed assets (gross block) ISO ISO End-to-end discovery and
Slide 19: Talented and Qualified Pool of Scientists
Talented and Qualified Pool of Scientists Highly Experienced and Qualified Team of Scientists has 12% of scientist pool with a Doctorate & 82% with a Master’s Degree Helped Syngene Create a Competitive Edge over its Peers Others Ph.Ds. Ability to attract and retain high-quality scientists 120 253
Slide 20: Attractive Blue Chip Customer Base
Attractive Blue Chip Customer Base Highly successful track-record in molecule Services to 221 Clients (FY15) development Across Various Sectors Client base includes 8 of the top 10 global pharma company by 2014 sales(1) Pharmaceutical 8 of our top 10 clients have been associated for Biotechnol
Slide 21: Long Term Relationships: Dedicated Research Centres
Long Term Relationships: Dedicated Research Centres Largest R&D Centre in Asia for BMS Dedicated research centre in India for Abbott Nutrition’s 1st R&D centre in India (2009). Contract extended till 2020. Baxter (2013). set up in collaboration with Syngene (2012). Dedicated centre of research excel
Slide 22: Multiple Layers of Growth
Multiple Layers of Growth Expand/Extend existing clients Capacity Expansion - High service integration - Consistent expansion - Dedicated centres model - FTE services, manufacturing, formulation, biologics, stability Engage New Clients - Tailored service offerings and Customer Capacity dedicated per
Slide 23: Financial Highlights
Financial Highlights . . 7 . + " » * * . waa eas! Putting Science to Work
Slide 24: Strong Track Record Of Topline Growth…
Strong Track Record Of Topline Growth… Growth driven by increase in sales from Total Revenue (INRm) existing clients and acquisition of new clients “Engage, expand and extend” strategy to extend client relationship over a longer 8,716 period of time 7,077 Growth in total number of clients 5,54
Slide 25: …With Best-in-Class Profitability
…With Best-in-Class Profitability Operating Margin (EBITDA) Profit After Tax Margin (Net Income) 20% 34% 34% 19% 17% 18% 31% 31% 30% 2,928 1,750 2,217 9% 1,339 1,682 976 1,404 727 1,005 283 FY2011 FY2012 FY2013 FY2014 FY2015 FY2011 FY2012 FY2013 FY2014 FY2015 EBITDA (INRm) EBITDA Margin Net Income (
Slide 26: Capital Expenditure
Capital Expenditure Historical Capital Investments – Average Gross Block (INRm) Planned Capital Expenditure 8,255 Capex of US$200 million envisaged over FY16 to FY18 5,610 6,149 6,819 5,216 Future funding requirements to be met through internal accruals and debt FY2011 FY2012 FY2013 FY2014 FY201
Slide 27: Efficient Use of Capital
Efficient Use of Capital Strong Balance Sheet with a Return on Capital Employed (ROCE)* Balance Sheet Balance Sheet Highlights Highlights Net cash of 977 Mn 22.6% 21.6% As on 30th June 2015 (INR Mn) 20.1% 20.2% Profitability resulting in high return on capital Shareholders’ funds 8,900 12.9% F
Slide 28: Summary: What Makes Syngene a Unique Investment Case?
Summary: What Makes Syngene a Unique Investment Case? INTEGRATED MODEL Integrated and flexible model provides predictability and scalability WORLD CLASS INFRASTRUCTURE & SCIENTISTS World class infrastructure, high standards of quality systems and a highly talented pool of scientists underpins the co
Slide 29: Managing Risks
Managing Risks Risk Mitigation Client growth and sustained retention Proactive client engagement and sustained quality Currency Fluctuation (USD/INR) comprehensive hedging policy and mechanism in place Significant Capex investment over next few years staggered investments in line with business visib
Slide 30: THANK YOU
THANK YOU For more details www.syngeneintl.com • Visit www.syngeneintl.com • IR Contact : Sweta Pachlangiya +91 80 2808 5481 [email protected]
Syngene International — Investor Presentation (August 2015) on 6ix